Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY

European Journal of Endocrinology

Volumn 161, Issue SUPPL. 1, 2009, Pages

  Brue, Thierry ^a,c   Castinetti, Frederic ^a   Lundgren, Frida ^b   Koltowska Häggström, Maria ^b   Petrossians, Patrick ^c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b PFIZER INC   (United States)

^c Registre Français de l'Acromégalie French Acromegaly Registry   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PEGVISOMANT; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE RECEPTOR; HORMONE ANTAGONIST; HUMAN GROWTH HORMONE;

ACROMEGALY; ADULT; AGED; CRANIOTOMY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STEREOTACTIC RADIOSURGERY; TRANSSPHENOIDAL SURGERY; ADOLESCENT; ARTICLE; BLOOD; DRUG ANTAGONISM; EUROPE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HOSPITALIZATION; HYPOPHYSIS TUMOR; INTERNATIONAL COOPERATION; INTERNET; LIVER FUNCTION TEST; METABOLISM; MIDDLE AGED; REGISTER; UNITED STATES;

ACROMEGALY; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; EUROPE; FEMALE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HEMOGLOBIN A, GLYCOSYLATED; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERNATIONAL COOPERATION; INTERNET; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; RECEPTORS, SOMATOTROPIN; REGISTRIES; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 70450080428     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0333     Document Type: Review

References (22)

1. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ & Lombardi G. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006 154 467-477.
2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177. (Pubitemid 30211048)
3. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759. (Pubitemid 33152999)
4. Marazuela M, Lucas T, Alvarez-Escola C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramirez M, Halperin I, Casanueva FF & Bernabeu I. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. European Journal of Endocrinology 2009 160 535-542.
5. Brue T. ACROSTUDY: status update on 469 patients. Hormone Research 2009 71 34-38.
6. Trainer PJ. ACROSTUDY: an overview. Hormone Research 2007 68 68-69.
7. Trainer PJ. ACROSTUDY: the first 5 years. European Journal of Endocrinology 2009 161 S19-S24.
8. Riis P. Thirty years of bioethics: the Helsinki Declaration 1964-2003. New Review of Bioethics 2003 1 15-25.
9. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K & Maiter D. AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. European Journal of Endocrinology 2007 157 399-409.
10. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M & Gilabert M. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). European Journal of Endocrinology 2004 151 439-446. (Pubitemid 39430260)
11. ReinckeM, Petersenn S, Buchfelder M, Gerbert B, Skrobek-Engel G, Franz H, Lohmann R & Quabbe HJ. The German Acromegaly Registry: description of the database and initial results. Experimental and Clinical Endocrinology and Diabetes 2006 114 498-505. (Pubitemid 44870898)
12. Castinetti F, Morange I, Dubois N, Albarel F, Conte-Devolx B, Dufour H & Brue T. Does first-line surgery still have its place in the treatment of acromegaly? Annales d'Endocrinologie 2009 70 107-112.
13. Castinetti F, Morange I, Dufour H, Regis J & Brue T. Radiotherapy and radiosurgery in acromegaly. Pituitary 2009 12 3-10.
14. Chanson P. Acromegaly. Presse Médicale 2009 38 92-102.
15. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K & Giustina A. Guidelines for acromegaly management: an update. Journal of Clinical Endocrinology and Metabolism 2009 94 1504-1517.
16. Strasburger CJ, Buchfelder M, Droste M, Mann K, Stalla GK & Saller B. Experience from the German pegvisomant observational study. Hormone Research 2007 68 70-73.
17. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B & Strasburger CJ. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007 156 75-82. (Pubitemid 46553905)
18. T'Sjoen G, Bex M, Maiter D, Velkeniers B & Abs R. Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. European Journal of Endocrinology 2007 157 411-417. (Pubitemid 350018443)
19. Neggers SJ, de Herder WW, Janssen JA, Feelders RA & van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogues and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. European Journal of Endocrinology 2009 160 529-533.
20. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de HerderWW & van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogues and pegvisomant in acromegaly. Journal of Clinical Endocrinology and Metabolism 2007 92 4598-4601.
21. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ & Gagel RF. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 2008 159 517-523.
22. Neggers SJ, van Aken MO, de HerderWW, Feelders RA, Janssen JA, Badia X,Webb SM & van der Lely AJ. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. Journal of Clinical Endocrinology and Metabolism 2008 93 3853-3859.